No abstract

The Procleix HEV ID-NAT screening system has provided evidence of HEV RNA presence in Catalan blood donors. Further data are needed to assess the impact of HEV infection in at-risk patients to design the best strategy to increase blood safety.

The results of this study emphasize the need for T. cruzi screening in at-risk blood donors in nonendemic countries. An important finding is the relevance of including in the at-risk category persons who have resided in, but were not necessarily born in, an endemic region. If T. cruzi screening is not routinely performed in all donations, it remains highly dependent on proper identification of at-risk donors during the predonation interview.